Powdered self-emulsified lipid formulations of meloxicam as solid dosage forms for oral administration

Drug Development and Industrial Pharmacy

Volumn 39, Issue 11, 2013, Pages 1681-1689

  Agarwal, Vikas ^a,b   Alayoubi, Alaadin ^c   Siddiqui, Akhtar ^c   Nazzal, Sami ^c  

^a CIMA a Cephalon Company   (United States)

^b TARIS Biomedical Inc   (United States)

^c UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

Adsorption; Bioavailability; Dissolution; Meloxicam; Self emulsified drug delivery systems

Indexed keywords

ATTAPULGITE; GELATIN; HYDROXYPROPYLMETHYLCELLULOSE; MELOXICAM; NEUSILIN US2; NONSTEROID ANTIINFLAMMATORY AGENT; RXCIPIENT GL100; SILICON DIOXIDE; UNCLASSIFIED DRUG; ZEOPHARM 5170;

ADSORPTION; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CRYSTAL; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; EMULSION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PARTICLE SIZE; POWDER; SELF EMULSIFIED DRUG DELIVERY SYSTEM; TABLET FORMULATION; X RAY DIFFRACTION;

ADMINISTRATION, ORAL; ANIMALS; ANIMALS, INBRED STRAINS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; BIOLOGICAL AVAILABILITY; CAPSULES; CYCLOOXYGENASE INHIBITORS; DOGS; DRUG COMPOUNDING; DRUG STABILITY; DRUG STORAGE; EMULSIONS; EXCIPIENTS; LIPIDS; PARTICLE SIZE; PHYSICOCHEMICAL PHENOMENA; POWDERS; SILICON DIOXIDE; SOLUBILITY; THIAZINES; THIAZOLES; TROMETHAMINE;

EID: 84885607851     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.729594     Document Type: Article

References (29)

1. Noble S, Balfour JA. (1996). Meloxicam. Drugs, 51:424-30; discussion 431
2. Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler C.(1995). Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res, 44:423-433
3. Seedher N, Bhatia S. (2003). Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS PharmSciTech, 4:E33
4. Bock T, Saegmueller P, Sieger P, Tuerck B. Meloxicam for oral administration. DE: Boehringer Ingelheim Pharma KG, Ingelheim (DE), 2005
5. Alayoubi A, Satyanarayanajois SD, Sylvester PW, Nazzal S.(2012). Molecular modelling and multisimplex optimization of tocotrienol-rich self emulsified drug delivery systems. Int J Pharm, 426:153-161
6. Khoo SM, Porter JH, Edwards GA, Charman WN. (1998). Metabolism of halofantrine to its equipotent metabolite, desbutylhalofantrine, is decreased when orally administered with ketoconazole. J Pharm Sci, 87:1538-1541
7. Hauss DJ, Fogal SE, Ficorilli JV, Price CA, Roy T, Jayaraj AA et al. (1998). Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J Pharm Sci, 87:164-169
8. Klauser RM, Irschik H, Kletzmayr J, Sturm I, Brunner W, Woloszczuk W et al. (1997). Pharmacokinetic cyclosporine A profiles under long-term Neoral treatment in renal transplant recipients: Does fat intake still matteróf Transplant Proc, 29:3137-3140
9. MacGregor KJ, Embleton JK, Lacy JE, et al. (1997) Influence of lipolysis on drug absorption from the gastro-intestinal tract. Advanced Drug Delivery Reviews, 25:33-46
10. Nazzal S, Wang Y. (2001). Characterization of soft gelatin capsules by thermal analysis. Int J Pharm, 230:35-45
11. Lu Y, Mei Y, Drechsler M, Ballauff M. (2006). Thermosensitive coreshell particles as carriers for ag nanoparticles: Modulating the catalytic activity by a phase transition in networks. Angew Chem Int Ed Engl, 45:813-816
12. Nazzal S, Nutan M, Palamakula A, Shah R, Zaghloul AA, Khan MA. (2002). Optimization of a self-nanoemulsified tablet dosage form of Ubiquinone using response surface methodology: Effect of formulation ingredients. Int J Pharm, 240:103-114
13. Pather SI, Gupte SV, Khankari RK, et al. Microemulsions as solid dosage forms for oral administration. Cima Labs Inc., 2001
14. Agarwal V, Siddiqui A, Ali H, Nazzal S. (2009). Dissolution and powder flow characterization of solid self-emulsified drug delivery system (SEDDS). Int J Pharm, 366:44-52
15. Nazzal S, Khan MA. (2006). Controlled release of a self-emulsifying formulation from a tablet dosage form: Stability assessment and optimization of some processing parameters. Int J Pharm, 315:110-121
16. Cannon JB. (2005). Oral solid dosage forms of lipid-based drug delivery systems. American Pharmaceutical Review, 8:108-115
17. Jannin V, Chambin O. Self emulsifying drug delivery systems.(2005). STP Pharma Pratique, 15:247-254
18. Yang KY, Glemza R, Jarowski CI. (1979). Effects of amorphous silicon dioxides on drug dissolution. J Pharm Sci, 68:560-565
19. Liao CC, Jarowski CI. (1984). Dissolution rates of corticoid solutions dispersed on silicas. J Pharm Sci, 73:401-403
20. Spireas S, Sadu S. (1998). Enhancement of prednisolone dissolution properties using liquisolid compacts. International Journal of Pharmaceutics, 166:177-188
21. Carr RL. Evaluating flow properties of solids. (1965) Chemical Engineering Journal, 18:163-168
22. Eglitis RI, Kuklja MM, Kotomin EA, et al. Structure and physicochemical properties of meloxicam, a new NSAID. (1996). European Journal of Pharmaceutical Sciences, 4:175-187
23. Yuan Y, Li SM, Mo FK, Zhong DF. (2006). Investigation of microemulsion system for transdermal delivery of meloxicam. Int J Pharm, 321:117-123
24. Nazzal S, Zaghloul A-A, Khan MA. Effect of Extragranular Microcrystalline Cellulose on Compaction, Surface Roughness, and In Vitro Dissolution of a Self-Nanoemulsified Solid Dosage Form of Ubiquinone. Pharmaceutical Technology, 2002
25. Kuminek G, Kratz JM, Ribeiro R, Kelmann RG, De Aräo BV, Teixeira HF et al. (2009). Pharmacokinetic study of a carbamazepine nanoemulsion in beagle dogs. Int J Pharm, 378:146-148
26. Lindeblad MO, Bauer KS, Zakharov AD, Hill JM, Green JS, Thomas BF et al. (2010). Pharmacokinetic and tissue distribution study of [14C]fluasterone in male Beagle dogs following intravenous, oral and subcutaneous dosing routes. Chem Biol Interact, 183:317-326
27. Ye X, Tang M, Liu J, Wang X, Ma L, Zheng H et al. (2011). Development and validation of a UPLC-MS/MS method for quantification of SKLB010, an investigational anti-inflammatory compound, and its application to pharmacokinetic studies in beagle dogs. J Pharm Biomed Anal, 56:366-372
28. Busch U, Schmid J, Heinzel G, Schmaus H, Baierl J, Huber C et al. (1998). Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Metab Dispos, 26:576-584
29. Kang BK, Lee JS, Chon SK, Jeong SY, Yuk SH, Khang G et al. (2004). Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm, 274:65-73